Yes, continue methotrexate at the current dose with routine monitoring
Given stable renal function (eGFR ≥ 60 mL/min/1.73 m²), normal liver enzymes, and normal complete blood count, methotrexate should be continued at the current weekly dose. This patient meets all safety criteria for ongoing therapy and demonstrates no laboratory evidence of toxicity.
Rationale Based on Guidelines
The multinational evidence-based recommendations explicitly state that methotrexate is appropriate for long-term use based on its acceptable safety profile 1. The patient's laboratory parameters fall well within safe ranges:
Liver function: Normal ALT/AST levels indicate no hepatotoxicity. Guidelines specify methotrexate should only be stopped if there is a confirmed increase in ALT/AST greater than three times the upper limit of normal 1. Your patient does not meet this threshold.
Renal function: With eGFR ≥ 60 mL/min/1.73 m², the patient has adequate renal clearance. Recent high-quality evidence from a randomized controlled trial demonstrated that low-dose methotrexate actually showed less eGFR decline compared to placebo in patients with baseline eGFR around 80 mL/min 2. Methotrexate is only contraindicated when creatinine clearance falls below 30-40 mL/min 3, 4.
Hematologic function: Normal CBC indicates no myelosuppression. The FDA label specifies methotrexate should be stopped immediately only if there is a significant drop in blood counts 3, which is not present here.
Monitoring Strategy Going Forward
Continue monitoring ALT/AST, creatinine, and CBC every 1-3 months as recommended for patients on stable doses 1. The 2009 multinational guidelines (Grade C recommendation) specify this frequency for patients who have reached a stable dose 1.
Recent 2026 evidence suggests that extending monitoring intervals to every 6 months may be safe and cost-effective for stable patients 5, 6, though this represents emerging practice rather than established guidelines. For now, quarterly monitoring (every 3 months) remains the standard of care.
Essential Concurrent Measures
Ensure the patient is taking at least 5 mg folic acid per week (Grade A recommendation) 1. This strongly recommended supplementation reduces gastrointestinal and hepatic toxicity without compromising efficacy 1.
Common Pitfalls to Avoid
Do not discontinue methotrexate based on minor, transient liver enzyme elevations below 3× upper limit of normal. These are common and usually not clinically significant 3.
Do not reduce the dose unnecessarily in patients with stable disease control and normal monitoring parameters. The evidence supports long-term use at effective doses 1.
Verify the patient understands weekly dosing (not daily). Mistaken daily use of the weekly dose has led to fatal toxicity 3.
Reassess if eGFR drops below 60 mL/min. Dose reduction to 50% is recommended when GFR falls between 30-60 mL/min 4.
When to Reconsider
Discontinuation or dose adjustment would only be warranted if:
- ALT/AST rises to >3× upper limit of normal on confirmed repeat testing 1, 7
- Development of significant cytopenias (WBC <3000/mm³, platelets <100,000/mm³) 3
- eGFR declines to <60 mL/min/1.73 m² (consider dose reduction) or <30-40 mL/min (discontinue) 3, 4
- New respiratory symptoms suggesting methotrexate pneumonitis 8, 3
- Patient develops intolerable side effects despite folic acid supplementation 9
The current clinical scenario represents optimal methotrexate therapy with appropriate safety monitoring—continue treatment.